Company intelligence / Profile preview

CytoCore

Ownership: Private
Development stage: Other

Overview

CytoCore developed FDA-approved sample collection devices and proteomic-based diagnostic tests for early detection of cervical and uterine cancers. Its main platform improves accuracy and accessibility of pre-cancer screening through advanced cell collection technology and automated image analysis. Some products are commercialized; others were in development or preparing for clinical studies by 2014

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic assay
Industry: Protein Biomarker Diagnostics

Partnerships

Grupo Palex – distribution agreement in Spain for SoftPap deviceMEDITE – merger/acquisition partnership expanding global reach in histology/cytology markets

Beyond the preview

Go deeper on CytoCore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoCore.

Explore the full profile